Pfizer-BioNTech’s COVID-19 vaccine just got a lot easier to transport and distribute – TechCrunch

The COVID-19 vaccine, developed by Pfizer and BioNTech, now has less stringent and excessive transport requirements than it was introduced. Originally, the mRNA-based vaccine had to be maintained at ultra-low temperatures throughout the transport chain – between −76 ° F and −112 ° F. New stability data collected by Pfizer and BioNTech, submitted to the US Food and Drug Administration (FDA) for review, is allowed to be stored in temps between 5 ° F and -13 ° F – the standard. Medical freezes are available in most clinics and care facilities.

The vaccine should remain stable for two weeks at a temperature that improves the flexibility of its options for transportation and last-mile storage in preparation for administration for patients. To date, the vaccine relies largely on existing “cold-chain” infrastructure, so that it is able to reach areas where it is being used to vaccinate patients. This limit is not for the modern vaccine, which is stable for up to a month at the standard temperature of a high fridge.

This development is just one example of how work is continuing on vaccines already being deployed under emergency approvals by health regulators in the US and around the world. Pfizer and BioNtech say they are working on bringing those storage temporary requirements down even further, so they can adopt the standard set by Modern Job.

Taken together with another fresh development, Israeli researchers study results Given that usually only one shot of the two-shot Pfizer-BioNTech vaccine can be 85% effective in itself, it is a major development for global immunization programs. The new requirements open up participation in a whole host of potential new players in delivery and delivery – including ride-hailing and large networks such as on-demand delivery players Amazon, which has offered its support to President Biden’s administration, And Uber, which is already working closely with Modern on vaccine education programs.

It also opens the door for participation in both the logistics and care delivery space from a range of startups and small companies that have no scale or specialized equipment to be able to offer extreme or cold-chain storage. Technical hurdles have been blockers for some, who have been looking for ways to help, but lacked the hardware and expertise needed to do so effectively.